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Abstract
Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate 
whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syn-
dromes—specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was 
assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia 
diagnosis were determined according to the Health of the Nation Outcome Scales’ mental and behavioural problem scores 
and the sample was divided into four groups: ‘agitation and psychosis’, ‘agitation, but no psychosis’, ‘psychosis, but no 
agitation’, and ‘neither psychosis nor agitation’. Antipsychotic prescription in a one-year window around first dementia 
diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models 
were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency 
hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, func-
tioning, as well as physical and mental health. Only in the group ‘psychosis, but no agitation’ (n = 579), 30% of whom were 
prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after 
adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09–4.25). An increased antipsychotic-related 
all-cause (adjusted HR 1.14; 95% CI 1.04–1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01–1.63) 
was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, 
the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting 
with psychosis without agitation, indicating the need for novel interventions for this group.
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Introduction
Neuropsychiatric symptoms, such as agitation and psychosis, 
are common and highly impactful complications of dementia 
[1] and are major determinants of poor quality of life, carer 
burden and healthcare costs. They are also associated with 
more rapid dementia progression and increased mortality 
[2, 3]. Antipsychotic medications are often considered in 
the management of these symptoms; however, while meta-
analyses indicate significant benefits, these are small, with 
Cohen’s d effect sizes lower than 0.2 across trials of antip-
sychotics to treat psychosis in Alzheimer’s disease [4–7].
These very modest benefits have to be balanced against 
potential harms, and concerns have been raised around an 
increased risk of mortality, cerebrovascular events and has-
tened cognitive decline in patients with dementia prescribed 
these agents [8, 9]. The US Food and Drug Administration 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1065 4-020-00643 -2) contains 
supplementary material, which is available to authorized users.
 * Christoph Mueller 
 christoph.mueller@kcl.ac.uk
1 King’s College London, Institute of Psychiatry, Psychology 
and Neuroscience, De Crespigny Park, London, UK
2 South London and Maudsley NHS Foundation Trust, 
London, UK
3 Stavanger University Hospital, Centre for Age-Related 
Disease, Stavanger, Norway
4 University of Exeter Medical School, Exeter, UK
 C. Mueller et al.
1 3
has issued a black box warning against the use of antip-
sychotic medication in dementia related psychosis and has 
not approved any antipsychotic medication for treatment of 
aggression in dementia [6]. Conversely, the European Medi-
cines Agency has approved risperidone as the only antipsy-
chotic for the short-term treatment of persistent aggression 
in patients with moderate to severe Alzheimer’s dementia 
who are not responsive to non-pharmacological interven-
tions and who pose a risk of harm to self or others [10].
Agitation and psychosis are nonetheless frequently inter-
linked in dementia [11] and there is an increasing recog-
nition that patient characteristics, especially the presence 
of certain neuropsychiatric symptoms, may be strong influ-
encers of risks related to antipsychotic prescribing [3, 12]. 
Using routinely collected and clinician-rated ‘real-world’ 
data on the hyperactivity and psychosis clusters of neuropsy-
chiatric symptoms in dementia [13], we aimed to investigate 
whether antipsychotic medications pose different hazards 
for adverse health outcomes in stratified analyses, in order 
to evaluate the potential for a more targeted approach to 
antipsychotic prescribing in dementia. The presence of addi-
tional cerebral pathologies in psychosis in dementia [14–17] 
suggests higher antipsychotic hazards in this group, but a 
substantial proportion of patients with psychosis in demen-
tia are not distressed or agitated [18]. As neuropsychiatric 
symptoms have been reported as potentially stronger cor-
relates of adverse outcomes than their treatments [19] (with 
agitation possibly yielding a higher risk than psychosis [3]) 
we hypothesized that patients with psychosis only might be 
at an increased risk of antipsychotic-related adverse out-
comes, while in other groups addressing the impact of the 
distress/aggression itself might partly counteract the adverse 
effects of antipsychotics. As secondary outcomes we evalu-
ated whether risks differed in relation to dementia subtype 
diagnosis or specific antipsychotic prescribed.
Methods
Data source
Data for this study were assembled using the South Lon-
don and Maudsley NHS Foundation Trust (SLaM) Clinical 
Record Interactive Search (CRIS) platform. SLaM serves a 
population of over 1.36 million residents, across four South 
London boroughs (Lambeth, Lewisham, Southwark, and 
Croydon) and is one of Europe’s largest healthcare provid-
ers for dementia and mental illness. Since 2006 all services 
in SLaM have adopted fully-electronic health records to 
enhance confidential and efficient storage of information. 
CRIS provides research access to over 400,000 anonymized 
health records from SLaM within a robust governance 
framework [20, 21] and has received ethical approval as an 
anonymized data resource (Oxford Research Ethics Com-
mittee C, reference 08/H0606/71+5).
We extracted data from structured fields routinely com-
pleted in the source record and from clinical documents. 
Identification of relevant information from free-text records 
was conducted through bespoke natural language (NLP) 
processing algorithms using the General Architecture for 
Text Engineering (GATE) software [22]. See supplementary 
document for a detailed description of the NLP algorithms 
applied to ascertain antipsychotic prescription, diagnosis 
and Mini-mental State Examination Score (MMSE) [23]. 
Further, CRIS has been linked to national data on hospitali-
sations (Hospital Episode Statistics (HES)) [24] and Office 
of National Statistics (ONS) death certificate data, enabling 
relevant health outcome data (mortality, hospitalisation) to 
be extracted for the current analyses.
Sample and stratification
We included patients who received a first diagnosis of 
dementia in SLaM services between 1st January 2007 and 
31st December 2015. Patients were excluded if they had a 
history of psychotic disorder prior to onset of dementia (as in 
this population antipsychotics are prescribed for functional 
psychosis rather than dementia), if they were diagnosed 
with a Lewy body dementia (as these pathologies inherently 
carry higher antipsychotic risks), and if they made use of 
acute hospital psychiatric liaison services in a six months (3 
months either side) window around dementia diagnosis (as 
these patients tend to have higher levels of co-morbidities 
and are more likely to be subject to short-term use of antip-
sychotics for delirium episodes).
To stratify the sample according to neuropsychiatric 
symptoms present at the time of dementia diagnosis, we 
used the Health of the Nation Outcome Scales (HoNOS) 
[25], whereby the score recorded closest to first dementia 
diagnosis was applied. The HoNOS is a validated and well-
established measure of patient wellbeing commonly used in 
UK mental health and dementia services and comprises 12 
clinician-rated subscales. Each subscale is rated from 0 (no 
problem) to 4 (severe or very severe problem). For ease of 
interpretation, the scores were dichotomised to ‘minor or 
no problems’ (scores 0 or 1) and ‘mild to severe problems’ 
(scores 2–4). ‘Agitation’ was defined on the basis of a score 
of at least two or more on the HoNOS ‘behavioural distur-
bance’ scale, and ‘psychosis’ on the basis of a score of two 
or more on the HoNOS ‘problems associated with halluci-
nations and/or delusions’ scale. Both items are associated 
with an increased all-cause mortality risk in populations of 
people with dementia [26, 27].
From this information, we created four groups: ‘agita-
tion and psychosis’ (Ag+P+), ‘psychosis, but no agitation’ 
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(Ag–P +), ‘agitation, but no psychosis’ (Ag+P–), and ‘nei-
ther agitation nor psychosis’ (Ag–P–).
To achieve one of our secondary objectives, we strati-
fied the sample according to dementia diagnosis subtype. 
The dementia subtype diagnosis was classified according 
to ICD-10 [28] through NLP supported by structured fields 
in the source record as follows: Alzheimer’s disease (F00.0 
and F00.1), vascular dementia (F01), mixed-type dementia 
(including Alzheimer’s disease and vascular dementia or 
F00.2) and other/unspecified dementia (F03 or no subtype 
mentioned).
Exposure and outcome variables
GATE-supported natural language processing algorithms on 
CRIS include one which ascertains pharmacotherapy from 
a comprehensive gazetteer of all past and current generic 
medication names (and most trade names); this was used to 
identify patients recorded as taking antipsychotic medica-
tions in a one year window (6 months either side) around 
first dementia diagnosis.
This medications application is designed to extract the 
names of medications that are inferred as currently pre-
scribed to the patient [29, 30] and is described in more detail 
in the accompanying supplementary document, including 
examples of text captured. The application was developed 
through expert annotation, whereby domain experts coded 
whether the medication prescription was present either based 
on their expert experience and/or pre-defined coding rules. 
Negation statements (e.g. ‘not using any antipsychotic’) are 
not specifically ascertained as a group, but are subsumed 
in the wider category of non-relevant statements [21]. The 
application preferentially detects medications with corre-
sponding dosage information, or where present use is explic-
itly mentioned (e.g. ‘currently on’) or is discernible through 
inference (e.g. ‘patient’ is faring better on risperidone). The 
precision for current use of antipsychotic medication across 
CRIS was found to be 81% and the recall of ever use of 
antipsychotic medication 77%.
First, all medications in chapter 4.2. (Central nervous 
system/Drugs used in psychoses and related disorders) of 
the British National Formulary [31] were considered as 
exposures. To examine whether specific antipsychotics dif-
fered in their hazard profile we further determined whether 
patients were prescribed risperidone, olanzapine, quetiapine, 
any second-generation antipsychotic or any first-generation 
antipsychotic.
In the whole cohort and aforementioned strata (neuropsy-
chiatric symptoms/subtype diagnoses) patients receiving any 
antipsychotic were compared to non-receivers in relation to 
adverse health outcomes. We established the time to events 
for each patient for the following four outcomes: (1) all-
cause mortality, (2) any emergency hospitalisation to acute 
care (non-psychiatric) hospitals [24], (3) hospitalisation 
due to stroke, and (4) stroke-specific mortality. Hospital-
ised stroke was defined on the basis of ICD-10 codes [28]. 
As the narrow definition of stroke (ICD-10 codes I61, I63, 
and I64) usually applied to national hospitalisation (HES) 
data [32] might miss a substantial proportion of confirmed 
stroke cases and misclassify a considerable number of sus-
pected strokes [33], we applied a wider definition identifying 
hospitalisations in which I60 to I67 (Cerebrovascular dis-
eases section) and G45 (Transient cerebral ischaemic attacks 
and related syndromes) were recorded as primary diagnosis 
in discharge documentation. We only considered the primary 
diagnosis to ensure that the stroke was a new event and the 
main cause for the hospitalisation. A patient was considered 
to have died of a stroke if the aforementioned ICD-10 codes 
were listed as underlying or primary cause of death on ONS 
death certificate data. Mortality data was available to a cen-
sus point on 10th December 2016 and hospitalisation data 
until a census point on 31st March 2016.
Covariates
From structured fields and supported by natural language 
processing applications we ascertained socio-demographic 
factors (age, gender, marital status, ethnicity, and a neigh-
bourhood-level index of multiple deprivation [34]), level of 
cognitive impairment (identified via MMSE score closest 
to the date of diagnosis [23]), and whether the patients had 
been hospitalised in the year before dementia diagnosis. 
In addition, we extracted data from the relevant remaining 
HoNOS subscales.
Statistical analyses
STATA 13 [35] was used for all analyses. Descriptive sta-
tistics were generated and presented accordingly. We con-
structed three Cox regression models to examine whether 
exposure to antipsychotics was related to the adverse out-
comes (hospitalisation, stroke, all-cause mortality, stroke-
specific mortality). Model 1 was adjusted for age and gender. 
Model 2 included age, gender, marital status, ethnicity, index 
of deprivation, MMSE score and dementia subtype (except 
in the analysis stratified for dementia subtype). In Model 3 
the items from Model 2 were included and we added HoNOS 
subscales (excluding agitation and psychosis when we strati-
fied for these variables) and previous hospitalisation.
First, we examined antipsychotic risks in the whole sam-
ple and then in the aforementioned strata (neuropsychiatric 
symptoms/subtype diagnoses). We further performed sepa-
rate analyses for each individual subgroup (symptom profile/
subtype diagnosis), comparing the HR in the subgroup to the 
HR in all other subgroups combined by including an interac-
tion term (treatment*subgroup) in Model 3. As the power of 
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the test for interaction is lower compared to the test of direct 
effects, we followed the recommendation to raise the type 
one error rate to increase power [36]. We elected to increase 
the error rate from 5% to 10% and considered interactions 
with p < 0.1 as true interactions. Lastly, again using the full 
sample, different antipsychotic medications were compared 
in relation to hazardous outcomes.
Of patients with HoNOS scores on agitation and psy-
chosis available at dementia diagnosis, 18% had missing 
data on at least one of the other covariates (most commonly 
MMSE (10%) or marital status (4%) were the only missing 
variables). As we judged missingness in this sample to be 
random, we imputed missing values using chained equations 
to maximise statistical power [37]. Using the mi package in 
STATA we created 20 imputed datasets through replacing 
missing values through simulated values assembled from 
covariates and outcome values. Rubin’s rules [38] were 
applied to combine coefficients in final analyses.
Results
We identified 14,093 patients diagnosed with dementia in 
SLaM services between 2007 and 2015. Of those, 1113 
patients were excluded as no baseline data was available 
on HoNOS ratings of agitation or psychosis, 502 patients 
with a diagnosis of a Lewy body dementia, 645 with a pre-
vious psychotic illness and 1727 patients as they made use 
of liaison psychiatry services at the time of diagnosis. The 
final sample consisted of 10,106 patients with a mean age 
at diagnosis of 81.1 (SD 8.7) years. Mean MMSE score at 
diagnosis was 18.7 (SD 6.4), 6384 (63.2%) patients were 
female and 1115 (11.0%) were prescribed an antipsychotic 
around the time of dementia diagnosis. See Fig. 1 for a flow-
chart of cohort composition and outcomes.
In total 4320 (42.8%) patients had Alzheimer’s disease 
(AD) recorded as diagnosis, 2553 (25.3%) had mixed-type 
dementia (Alzheimer’s disease and vascular dementia), 
1910 (18.9%) had vascular dementia, and 1323 (13.1%) 
were diagnosed as having other or unspecified dementia. 
Antipsychotic prescribing at the time of dementia diagnosis 
was most prevalent in those with other/unspecified dementia 
(17.9%), followed by vascular dementia (15.4%) and was 
least likely in those with Alzheimer’s disease (8.4% in pure 
AD and 8.7% in mixed-type dementia).
Adverse outcomes associated with antipsychotic 
prescribing in the whole sample
Of the whole cohort, 5373 (53.2%) patients died in the fol-
low-up period with a median survival time of 4.29 years 
(interquartile range 2.02–7.60  years). Moreover, 6797 
(67.3%) had at least one emergency hospitalisation, 670 
(6.6%) were recorded as having a hospitalised stroke and 
619 (6.1%) died of a stroke according to their death cer-
tificate. In Cox regression models adjusting for age, gen-
der, ethnicity, marital status, MMSE, deprivation score and 
dementia subtype (Model 2), antipsychotic prescription was 
related to an increased risk of all-cause mortality (hazard 
ratio (HR) 1.22; 95% CI 1.12–1.32) and stroke-specific 
mortality (HR 1.27; 95% CI 1.02–1.60), but not for emer-
gency hospitalisation (HR 1.07; 95% CI 0.99–1.15) or hos-
pitalised stroke (HR 1.02; 95% CI 0.80–1.29). After further 
adjustment for HoNOS scores and previous hospitalisation 
(Model 3), an increased all-cause mortality risk (HR 1.14; 
95% CI 1.05–1.24) and stroke-specific mortality risk (HR 
1.28; 95% CI 1.01–1.63) remained, but no significant effects 
14,093 patients diagnosed with dementia 2007-2015 identified
3,987 patients excluded:
- 1,113 no baseline data on agitation or psychosis
- 502 with a diagnosis of a Lewy body dementia
- 645 with previous psychotic illness
- 1,727 under liaison psychiatry at the time of diagnosis
10,106 patients in the final sample
1,115 (11.0%) were prescribed an antipsychotic*
- 283 (2.8%) Risperidone
- 162 (1.6%) Olanzapine
- 402 (4.0%) Quetiapine
- 889 (8.8%) Any second- generation antipsychotic
- 386 (3.8%) Any first-generation antipsychotic antipsychotic
Dementia subtype diagnoses:
- 4,320 (42.8%) Alzheimer’s disease
- 1,910 (13.1%) Vascular dementia
- 2,553 (25.3%) Mixed-type dementia
- 1,323 (13.1%) Unspecified dementia 
Agitation & psychosis 
(Ag+P+; n=481; 4.8%)
Psychosis, but no agitation 
(Ag-P+; n=579; 5.7%)
Agitation, but no psychosis 
(Ag+P-; n=1,325; 13.1%)
Neither agitation nor psychosis 
(Ag-P-; n=7,721; 76.4%)
206 (42.8%) on antipsychotic:
139 (67.5%) died
145 (70.4%) emergency  hospitalisation
11 (5.3%) stroke hospitalisation
13 (6.3%) died of stroke
275 (57.2%) not on antipsychotic:
172 (62.6%) died
196 (71.3%) emergency hospitalisation
15 (5.5%) stroke hospitalisation
17 (6.2%) died of stroke
405 (70.1%) not on antipsychotic:
232 (57.1%) died
286 (70.4%) emergency hospitalisation
22 (5.4%) stroke hospitalisation
26 (6.4%) died of stroke
173 (29.9%) on antipsychotic:
117 (67.6%) died
138 (79.8%) emergency hospitalisation
17 (9.8%) stroke hospitalisation
17 (9.8%) died of stroke
298 (22.5%) on antipsychotic:
210 (70.5%) died
196 (65.4%) emergency hospitalisation
18 (6.0%) stroke hospitalisation
26 (8.7%) died of stroke
1,027 (77.5%) not on antipsychotic:
661 (64.4%) died
710 (69.1%) emergency hospitalisation
60 (5.8%) stroke hospitalisation
67 (6.5%) died of stroke
438 (5.7%) on antipsychotic:
269 (61.4%) died
301 (68.7%) emergency hospitalisation
31 (7.1%) stroke hospitalisation
34 (7.8%) died of stroke
7,283 (94.3%) not on antipsychotic:
3,573 (49.1%) died
4,826 (66.3%) emerg. hospitalisation
496 (6.8%) stroke hospitalisation
419 (5.8%) died of stroke
Stratification according to HONoS65+ problem scores
* Some patients had several antipsychotics mentioned in their record
Fig. 1  Flow chart
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were detected in relation to emergency hospitalisation or 
stroke (see Table 4 for Model 3 and Supplementary Table 1 
for results of all models).
Characteristics of the sample stratified according 
to neuropsychiatric symptom profile
In our sample 23.6% of patients presented with hyperactiv-
ity and psychosis neuropsychiatric symptoms at the time of 
dementia diagnosis; whereby agitation was present in 17.9% 
and psychosis in 10.5% of the sample. According to our 
group definitions, 481 (4.8%) presented with ‘agitation and 
psychosis’ (Ag+P+), 579 (5.7%) with ‘psychosis, but no 
agitation’ (Ag–P +), 1325 (13.1%) with ‘agitation, but no 
psychosis’ (Ag+P–) and the remaining 7721 patients with 
neither of the two neuropsychiatric symptoms (Ag–P–).
Sample characteristics and comparisons between groups 
are presented in Table 1. In comparison to those without 
either symptom, patients with agitation and/or psychosis had 
a lower MMSE at diagnosis, lived in more deprived neigh-
bourhoods, were less likely to have a diagnosis of Alzhei-
mer’s disease and more likely to be diagnosed with vascular 
or unspecified dementia, showed an increased occurrence of 
depressed mood, as well as physical health and functional 
problems. Amongst those with neuropsychiatric symptoms, 
patients with ‘psychosis, but no agitation’ (Ag–P +) were 
more likely to be female, less likely to be married or cohabit-
ing, had a higher MMSE score, were less likely to have sub-
stance use, self-harm, physical health or functional problems 
(with the exception of living conditions). The Ag+P+ group 
included the highest proportion of patients prescribed antip-
sychotics (42.8%), followed by 29.9% in the Ag–P + group 
and 22.5% in Ag+P– group.
Table 1  Sample characteristics by neuropsychiatric symptom profile
*Significantly different to group Ag–P– (p < 0.05); #significantly different to group Ag–P + (p < 0.05)
a ANOVA or  Chi2 test; bat the time of dementia diagnosis; cin a one-year window around dementia diagnosis; din the year prior to dementia diag-
nosis
Risk factors Agitation and 
psychosis 
(Ag+P+)
(n = 481)
Psychosis, but no 
agitation (Ag–P +)
(n = 579)
Agitation, but no 
psychosis (Ag+P–) 
(n = 1325)
Neither agitation nor 
psychosis (Ag–P–) 
(n = 7721)
P  valuea
Socio-demographic status and cognitive functionb
Mean age at dementia diagnosis (SD) 81.3 (10.1) 81.8 (9.1) 81.0 (9.2) 81.1 (8.5) 0.267
Female gender (%) 62.6%# 69.3%* 57.6%*,# 63.7%# < 0.001
Non-White ethnicity (%) 27.8% 31.3%* 23.3%# 24.0%# < 0.001
Married or cohabiting status (%) 31.4%# 24.8%* 34.8%# 34.9%# < 0.001
Mean index of deprivation (SD) 28.9 (10.3)* 28.2 (10.9)* 28.8 (10.7)* 26.6 (11.1)# < 0.001
Mean MMSE score at diagnosis (SD) 15.6 (7.1)*,# 17.6 (6.5)* 15.3 (7.3)*,# 19.5 (6.0)# < 0.001
Dementia subtype < 0.001
Alzheimer’s disease 31.0%* 35.1%* 32.2%* 45.9%#
Mixed-type dementia (including Alzhei-
mer’s disease and Vascular dementia)
23.7% 24.5% 22.9%* 25.8%
Vascular dementia 25.8%*,# 22.5%* 25.4%* 17.1%#
Unspecified or other dementia 19.5%* 18.0%* 19.6%* 11.2%#
HoNOS symptoms/disorders (%)b
Non-accidental self-injury 4.4%*,# 1.4% 3.0%*,# 0.7% < 0.001
Problem-drinking or drug taking 6.5%*,# 2.9% 5.4%*,# 2.5% < 0.001
Depressed mood 27.0%*,# 20.9%* 21.9%* 12.5%# < 0.001
Physical illness or disability 68.4%*,# 60.8%* 65.4%* 47.3%# < 0.001
HoNOS functional problems (%)b
Activities of daily living 82.5%*,# 70.6%* 81.3%*,# 51.6%# < 0.001
Living conditions 21.3%* 18.9%* 18.0%* 9.3%# < 0.001
Occupational/recreational activities 53.5%*,# 38.6%* 49.9%*,# 27.7%# < 0.001
Social relationships 52.2%*,# 17.4%* 45.6%*,# 8.3%# < 0.001
Antipsychotic  prescriptionc 42.8%*,# 29.9%* 22.5%*,# 5.7%# < 0.001
 Hospitalisation prior to dementia 
 diagnosisd
52.6%* 48.0% 50.8%* 46.1% < 0.001
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Hazards related to antipsychotic prescribing 
in the four neuropsychiatric symptom subgroups
Multivariate Cox regression models (Model 3; see Table 2) 
showed a 116% and significantly increased stroke hospitali-
sation risk associated with antipsychotic prescribing in the 
Ag–P + group, whereby no increased hazard was detected in 
any of the other groups.
An interaction between antipsychotic prescribing and the 
Ag–P + group (when comparing to the hazard in all other 
subgroups combined) in relation to stroke hospitalisation 
could further be identified (p = 0.064) strengthening the find-
ing that antipsychotic-related risk of hospitalisation due to 
stroke might be higher in this group (see Supplementary 
Table 2).
Whereby an increased antipsychotic mortality risk was 
detected in a Cox regression model adjusted for age, gen-
der, marital status, ethnicity, index of deprivation, MMSE 
score, and dementia subtype (Model 2) in the Ag+P– and 
the Ag–P– group, this was no longer significant after further 
adjustment (Model 3). No increased risks of emergency hos-
pitalisation or stroke-specific mortality were detected in rela-
tion to any of the groups in adjusted models (Model 2 and 3).
This was mirrored in non-significant interaction terms for 
the association between strata and antipsychotic prescribing 
in relation to the adverse health outcomes (see Supplemen-
tary Table 2). Although a 20% increased risk of emergency 
hospitalisation in the Ag–P + group only amounted to a 
non-significant trend (p = 0.096), the interaction term was 
significant (p = 0.042) indicating that antipsychotic-related 
emergency hospitalisation risk might be higher in patients 
with this symptom profile than in the remainder of the sam-
ple. The absence of evidence for an increased antipsychotic-
related all-cause mortality risk by neuropsychiatric symptom 
strata was reflected the p values of the interaction terms. A 
significantly increased antipsychotic-related all-cause mor-
tality risk was identified for those not in the A+P+ group. 
Together with p value of 0.076 for the interaction term this 
indicates that there might be a lower antipsychotic-related 
all-cause mortality risk in patients who don’t suffer from 
co-morbid agitation and psychosis.
Hazards related to antipsychotic prescribing 
in the four dementia subtype groups
Multivariable Cox proportionate hazard models adjusted for 
age, gender, ethnicity, deprivation and MMSE (Model 2; see 
Table 3) showed an increased antipsychotic-related all-cause 
mortality and hospitalisation risk in patients diagnosed with 
Alzheimer’s disease, as well as an increased antipsychotic-
related all-cause mortality risk in patients diagnosed with 
vascular dementia. After further adjustments for previous 
hospitalisation and HoNOS scores (including agitation and Ta
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psychosis) a significantly increased antipsychotic-related 
mortality risk remained in patients diagnosed with Alzhei-
mer’s disease (22% increase) and vascular dementia (29% 
increase). Further, patients with mixed-type dementia had a 
65% and significantly increased risk of stroke hospitalisation 
associated with antipsychotic prescribing.
When testing for interactions (Supplementary Table 3), 
the increased antipsychotic related all-cause mortality risk 
was strengthened in the vascular dementia group (p = 0.090), 
but not in the Alzheimer’s disease group (p = 0.571). A sig-
nificantly increased antipsychotic-related all-cause mortality 
risk was identified for those not in the mixed-type dementia 
group. Together with p value of 0.001 for the interaction 
term this indicates that there might be a lower antipsychotic-
related all-cause mortality risk in patients with mixed-type 
dementia. For none of the other analyses p values for inter-
action < 0.1 were identified, but the there was an indication 
(p = 0.130) that the increased antipsychotic-related stroke 
risk in those diagnosed with mixed-type dementia might be 
true.
Comparison of specific antipsychotics in relation 
to adverse outcomes
Cox proportionate hazard models evaluating specific 
antipsychotic medications against no antipsychotic or any 
other antipsychotic are presented in Table 4 (only Model 
3) and Supplementary Table 1 (Models 1, 2, 3). Whilst, as 
aforementioned, an increased all-cause and stroke-specific 
mortality risk was identified for use of any antipsychotic 
compared to non-use, this could only be replicated with 
significant findings for second generation antipsychotics 
(15% increased all-cause mortality risk and 31% increased 
stroke-specific mortality risk compared to no use of an antip-
sychotic). Largest all-cause mortality risk increase appeared 
to be associated with risperidone, although this amounted 
to non-significant trend (p = 0.062). Direct comparisons in 
subgroups of antipsychotic users didn’t detect any signifi-
cant differences between users of specific antipsychotics and 
users of any other antipsychotic; neither did the comparison 
between first- and second-generation antipsychotics.
Discussion
In a large naturalistic sample of patients diagnosed in a spe-
cialist service for dementia and mental health care, we found 
that patients with dementia rated by clinicians to have prob-
lematic psychosis, but not co-morbid agitation or agitation 
alone, were at an increased risk of stroke associated with 
antipsychotic use.
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A higher all-cause and stroke-specific mortality risk 
related to antipsychotic prescribing was detected in the 
whole sample. There was no true interaction between neu-
ropsychiatric symptom strata and antipsychotic-related mor-
tality risk, with the exception of a possibly higher antipsy-
chotic-related mortality risk in those not in the agitation and 
psychosis group.
Further, an increased antipsychotic-related all-cause mor-
tality risk was identified for patients with Alzheimer’s dis-
ease and vascular dementia, whereby an interaction between 
dementia subtype strata and antipsychotic mortality risk 
could only be identified for vascular dementia.
In the whole sample, second-generation antipsychotics 
were associated with an increased all-cause and stroke-
related mortality risk compared to non-use, and this asso-
ciation amounted to a trend for risperidone. No other spe-
cific antipsychotic was significantly associated with a higher 
risk of adverse outcomes, neither in comparison to all other 
antipsychotic users nor non-users.
Almost half of those presenting with agitation and psy-
chosis (Ag+P+) were prescribed antipsychotics, indicating 
a group in whom clinicians saw the greatest need for treat-
ment, followed by those with psychosis alone, 30% of whom 
had antipsychotic treatment recorded. In our sample 24% of 
patients presented with neuropsychiatric symptoms at the 
time of dementia diagnosis, a symptom prevalence which is 
slightly lower than reported in previous research [3, 39]. The 
likely reason for this is that we excluded symptoms classi-
fied as ‘minor problem, requiring no action’ on the HoNOS 
scale, which might be included if a structured research scale 
is applied and recording is likely to be less rigorous in rou-
tinely collected data than in screened research samples.
The excess stroke risk associated with antipsychotic use 
in the Ag–P + group highlights challenges in the treatment 
of psychosis in dementia for which antipsychotics are fre-
quently used. They are known to have at best modest efficacy 
in these circumstances and important side effect risks. In 
addition to the effects found in this study, antipsychotics are 
also associated with accelerated cognitive decline, sedation 
and extrapyramidal symptoms [6, 9, 40].
The results of this study differ from a meta-analysis data 
of data from 1721 patients included in randomised controlled 
Table 4  Risks of adverse outcomes according to specific antipsychotic type using Cox proportional hazard models (Hazard ratios (95% CI))
Adjusted for age, gender, marital status, ethnicity, index of deprivation, MMSE score, dementia subtype, HoNOS scores (agitation, psychosis, 
non-accidental self-injury, problem-drinking or drug taking, depressed mood, physical illness or disability, activities of daily living, living condi-
tions, occupational/recreational activities, social relationships), and hospitalisation in the year prior to dementia diagnosis (Model 3)
Bold p < 0.05
Italics 0.05 < p < 0.10
The antipsychotic first mentioned can also be in combination (e.g. if risperidone prescribed in combination, it is grouped in the risperidone 
group)
* SGA versus FGA excludes combinations of second-generation with first-generation antipsychotics (n = 163)
Mortality Any emer-
gency hospi-
talisation
Stroke hospitalisation Stroke-specific mortality
Any antipsychotic (n = 1115) versus no antipsychotic 
(n = 8991)
1.14
(1.04–1.24)
0.99
(0.92–1.08)
1.09
(0.84–1.40)
1.28
(1.01–1.63)
Risperidone (n = 283) versus any other antipsychotic 
(n = 832)
1.03
(0.86–1.22)
1.00
(0.84–1.18)
0.82
(0.46–1.44)
1.07
(0.65–1.75)
Risperidone (n = 283) versus no antipsychotic (n = 8991) 1.16
(0.99–1.36)
0.99
(0.85–1.15)
0.93
(0.55–1.57)
1.34
(0.85–2.11)
Olanzapine (n = 162) versus any other antipsychotic 
(n = 953)
1.02
(0.81–1.29)
0.81
(0.65–1.00)
0.77
(0.36–1.61)
1.27
(0.68–2.35)
Olanzapine (n = 162) versus no antipsychotic (8991) 1.16
(0.93–1.45)
0.83
(0.67–1.01)
0.86
(0.42–1.75)
1.58
(0.88–2.83)
Quetiapine (n = 402) versus any other antipsychotic 
(n = 713)
0.95
(0.82–1.10)
1.12
(0.97–1.30)
1.38
(0.88–2.16)
0.92
(0.60–1.41)
Quetiapine (n = 402) versus no antipsychotic (n = 8991) 1.11
(0.98–1.25)
1.07
(0.95–1.20)
1.30
(0.92–1.84)
1.22
(0.86–1.73)
Any second-generation (n = 889) antipsychotic versus no 
antipsychotic (n = 8991)
1.15
(1.05–1.26)
1.02
(0.93–1.11)
1.13
(0.86–1.49)
1.31
(1.00–1.70)
Any first-generation (n = 386) antipsychotic versus no 
antipsychotic (n = 8991)
1.10
(0.96–1.25)
0.94
(0.82–1.06)
1.06
(0.71–1.58)
1.12
(0.76–1.65)
Any first-generation antipsychotic (n = 223) versus any 
second-generation (n = 762) antipsychotic*
0.95
(0.79–1.14)
0.89
(0.74–1.07)
0.86
(0.48–1.57)
0.84
(0.49–1.44)
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trials of risperidone [12], which found that in those with 
delusions at baseline (as identified on the Behavioral Pathol-
ogy in Alzheimer’s Disease (BEHAVE-AD) scale [41]), 
the risperidone-related stroke risk was not significantly 
increased (HR 1.47; 95% CI 0.59–3.65) as distinct from a 
raised risk in those who did not present with delusions (HR 
5.88; 95% CI 2.09–16.53). Several explanations exist for 
these differences: While risperidone trials used a structured 
measure (BEHAVE-AD [41]), our classification of psychotic 
symptoms was according to the relevant HoNOS subscale. 
In this measure, the clinician rates if the neuropsychiatric 
symptom cluster poses a problem for the patient and their 
environment rather than describing the nature of the psy-
chotic symptom. Further the inclusion criteria differed 
between the meta-analysis and our study. Risperidone tri-
als [12] only included patients if they displayed psychosis 
or scored above a threshold on BEHAVE-AD [41], leading 
to a mixed population of patients with psychosis, agitation 
or a combination of neuropsychiatric symptoms. Our study 
aimed to examine agitation and psychosis as combined 
or mutually exclusive. We aimed to assess a class effect of 
antipsychotics in relation to neuropsychiatric symptom pro-
files and did not investigate specific properties of individual 
medications in relation to the strata. It should also be borne 
in mind that clinical trials inevitably recruit rather selected 
samples, whereas our cohort may be more representative of 
the treated population.
There are several explanations why patients with demen-
tia presenting with psychotic symptoms might be at a higher 
risk of antipsychotic-related stroke. First, the presence of tau 
pathology has both been linked to the presence of psychotic 
symptoms and an adverse prognosis in Alzheimer’s disease 
[17, 42, 43]. Evidence from mouse models suggests that tau 
mediates excitotoxicity after cerebrovascular events [44]. It 
is therefore possible that small cerebrovascular events trig-
gered by antipsychotic-related excessive sedation, dehydra-
tion or orthostatic hypotension [45] might lead to a deficit 
in brain perfusion, and the response to this deficit might be 
exaggerated to toxic levels in the presence of tau pathology, 
ultimately leading to a hospitalised stroke [44]. In addition, 
a recent study of autopsied cases of AD demonstrated that 
cerebral amyloid angiopathy and advanced small vessel dis-
ease were more common in AD patients with psychosis than 
in those without psychosis [15]. Although its role in the 
neurodegenerative process is not fully understood, cerebral 
amyloid angiopathy weakens cerebral blood vessels [46] and 
can lead to microbleeds or larger haemorrhages. It is there-
fore possible that psychosis in Alzheimer’s disease is related 
to vascular fragility, and antipsychotics might increase risk 
of stroke via the aforementioned mechanisms.
Moreover, there is an increasing recognition that patients 
diagnosed with a single dementia subtype, as Alzheimer’s 
disease, frequently have co-morbid cerebral pathologies, as 
Lewy bodies, vascular pathology, or TDP-43 proteinopathy, 
when autopsied [47]. The presence of Lewy bodies is associ-
ated with a higher frequency of visual hallucinations [47–49] 
as well as with sensitivity reactions to antipsychotic medica-
tions, and might thereby explain in part the increased risk of 
adverse outcomes [16, 50].
We didn’t not find evidence for an increased antipsy-
chotic-related stroke risk in patients with agitation, both in 
those with and those without co-morbid psychosis. While 
pathological and anatomical changes in psychosis in demen-
tia have been extensively studied and also distinguished from 
psychosis in schizophrenia [51], less is known about agita-
tion in dementia. Agitation in dementia has been associ-
ated with frontal lobe dysfunction [52] and brain regions 
involved in subjective emotional experiences [53]. It has 
been hypothesised that agitation could arise from overes-
timating or misinterpreting potential threats [54], whereby 
those threats could for example be pain or changes in the 
environment. It is however also conceivable that, as pos-
sibly in the agitation and psychosis group, those overinter-
preted threats are psychotic or quasi psychotic experiences. 
Further research is required to clarify the neuropathological 
corelates of agitation in dementia, especially distinguish-
ing between ‘agitation as a syndrome’ from ‘agitation as 
response to another disorder’ (e.g. agitation and psychosis) 
[52], which could also elucidate possible mechanisms for 
differences in antipsychotic hazards compared to those with 
only psychosis.
When we stratified by dementia subtype, we identified a 
robust 29% increased antipsychotic related mortality risk in 
patients diagnosed with vascular dementia. This is different 
from a previous study by Sultana and colleagues in this data 
source [30], which might be grounded in two key differ-
ences between the two studies: First, we ascertained preva-
lent use of antipsychotic medication at dementia diagnosis 
and the previous study antipsychotic use at any timepoint 
after dementia diagnosis. Second, Sultana and colleagues 
only included second-generation (atypical) antipsychotics, 
while our study evaluated the impact of all classes of antip-
sychotics and first-generation antipsychotics have recently 
been shown to yield a higher mortality risk in those with 
cardiovascular or cerebrovascular disease [55].
We could only identify a class effect for all antipsychot-
ics and second-generation antipsychotics in relation to mor-
tality risk. Although no significant results were obtained, 
there was a trend towards a higher mortality risk in those 
taking risperidone, which was also the largest group tak-
ing a specific antipsychotic. In line with previous research 
[56], Quetiapine appeared to yield lowest risk of mortality. 
The absence of evidence for increased hazards in the first-
generation antipsychotic group is in line with a recent study 
[57] showing that patients with Alzheimer’s disease using 
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first-generation antipsychotics had a lower risk of death than 
those using second-generation antipsychotics.
Finally, although this cannot be derived from our data, the 
dose and antipsychotic agent used might differ between pre-
scription for agitation and for psychosis in dementia. While 
clear guidance exists in the UK and Europe for cautious 
management of agitation [10, 58], prescribing for psychosis 
is off-label and clinicians might use higher doses leading to 
an increased excess risk of harm [56].
Strengths of this study include the large naturalistic sam-
ple of patients diagnosed with dementia by a near-monopoly 
dementia care provider for its catchment population. The 
use of clinician-rated real-world measures of neuropsychi-
atric problems should also give a clinically relevant picture. 
MMSE scores in our sample were higher than in most clini-
cal trials conducted on antipsychotics in people with demen-
tia, which largely include participants in the severe stage of 
illness [12]. For this reason, similar to CATIE-AD [59], our 
findings might be more applicable in earlier disease stages 
and thereby more relevant to patients and their families. The 
richness of this data allowed adjustment for a wide range of 
confounders, and the linkage to national data on mortality 
and hospitalisation should have resulted in close to complete 
ascertainment of outcome data. A particular advantage of 
NLP is that the applications account for the linguistic con-
text of a statement of interest in free text, enabling exclusion 
of negation and other irrelevant statements and ascertaining 
current, rather than past, prescription or speculations about 
future prescribing [29]. However, the use of routinely col-
lected electronic health record data also presents a number of 
limitations. First, consistent recording of patient information 
is only available at certain time points of the patient’s jour-
ney through the healthcare system. Therefore, we chose to 
ascertain recording of neuropsychiatric symptoms and antip-
sychotic prescription in the most reliable window around 
the time of first dementia diagnosis. Second, we could 
extract information on the initiation of antipsychotic agents 
and on use at given times, but we were not able to track 
antipsychotic prescription longitudinally. However, hazard-
ous effects of antipsychotics are already present when only 
prescribed short-term [60] and the agents are unlikely to be 
withdrawn in the absence of effective alternative interven-
tions [61]. Nevertheless, exclusively considering exposure 
to antipsychotics around the time of diagnosis leads to indi-
viduals prescribed antipsychotics in a later stage of dementia 
not being considered as exposed, which could potentially 
bias estimates towards the null and is particularly relevant 
to the null finding in the relatively small Ag+P+ group. This 
group is more than 2.5 times smaller than the other groups, 
which might have resulted in a lack of power in adjusted 
analyses. Third, in addition to the aforementioned challenges 
with data availability and temporality further limitations of 
ascertaining variables through NLP from clinical records 
need to be acknowledged: The output depends on the accu-
racy and quality of data entry, which varies by individual 
clinician and is compromised through the use of jargon, 
idiosyncratic abbreviations or misspellings [21]. Although 
precision and recall are relatively high for the medication 
NLP application, there remains a risk under- or overesti-
mating the true prescribing prevalence. Moreover, there is 
a possibility of misclassification of the reason for stroke-
related hospitalisation or death. As we only used the first 
discharge diagnosis in order to ascertain new cerebrovas-
cular events, strokes that occurred in the context of another 
medical event might have been missed, potentially leading to 
under-recording and underestimation of effects. The broader 
definition of the stroke outcome according to ICD-10 was 
used to reflect the uncertainty which often exists around cer-
ebrovascular events in hospital settings, where distinction 
from TIA or other ‘stroke mimics’ is often not possible in 
the short time-frame of the admission [33], but this approach 
might also lead to a higher detection of false positives. That 
we are only detecting an increased antipsychotic-related risk 
of hospitalised stroke in the Ag–P +, but no increased risk 
of stroke-related mortality, could reflect that those patients 
are experience signs of stroke but not necessarily cerebro-
vascular changes. Conversely, death certificate data is prone 
to classification bias and sensitivity for recording of stroke 
on death certificate has been shown to be below 71% in most 
studies [62]. Fourth, we were only able to examine indi-
vidual antipsychotics across the whole sample and did not 
seek to analyse by type of antipsychotic or individual agent 
in analyses stratified by neuropsychiatric symptom profile 
or subtype diagnosis. Heterogeneity by agent or sub-class 
can therefore not be excluded in these analyses. Fifth, physi-
cal health was ascertained through previous hospitalisation 
and the HoNOS ‘Physical illness and disability problems’ 
subscale. The latter, although widely used in clinical mental 
health services in the UK and consistently showing relations 
with important outcomes [26], is a relatively brief meas-
ure without detailed information on the conditions deter-
mining its score. Sixth, data on level of education was not 
available, and socio-economic status was only ascertained 
at neighbourhood rather than individual level [34]. Thus, 
although we were able to adjust for a range of demographic, 
clinical, social and functional covariates, residual confound-
ing cannot be fully excluded. This is particularly relevant for 
smaller subgroups (as Ag+P+) where adjustment for con-
founders might not fully account for differences in baseline 
variables and correlation does not necessarily infer causal-
ity. An important consideration for pharmacoepidemiologic 
studies is confounding by indication, whereby individuals 
with more severe symptoms are more likely to be prescribed 
medications. We stratified patients by the presence of agita-
tion and/or psychosis according to a well-being score but 
could not measure severity of these symptoms. As stroke 
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prior to onset of Alzheimer’s disease has been described as 
associated with a higher risk of delusions [14], higher levels 
of cerebrovascular morbidity might be present a priori in 
patients with psychosis prescribed an antipsychotic. Lastly, 
for the purpose of this study we only examined whether 
antipsychotic-related hazards differed in relation to agita-
tion and psychosis as these are the two main indications for 
antipsychotic use in dementia. Future studies could examine 
whether degree of cognitive impairment, overall neuropsy-
chiatric symptom burden or other specific neuropsychiatric 
symptoms (e.g. depression or anxiety) affect antipsychotic 
hazards, which could feed into more advanced prediction 
models and potentially translate into real-time risk detection 
and alerting systems [63].
Conclusions
Our data suggests that antipsychotic use is associated with 
more than a doubling of risk of cerebrovascular events in 
patients with dementia suffering from psychosis (without 
agitation). Advocacy for avoidance of antipsychotics has 
been strongest in for agitation in dementia [58], but this 
might be equally, or even more important, in those present-
ing with psychosis. While non-pharmacological manage-
ment strategies of psychosis are becoming more accepted 
in the field of functional psychotic disorders [64], there is 
little evidence available on the efficacy of such interventions 
in dementia [65] and novel strategies to address distressing 
psychotic symptoms in dementia clearly need further devel-
opment and evaluation.
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